|
1
|
de Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
2
|
Tournigand C, André T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan and oxaliplatin combinations in patients with previously
untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30.
2004. View Article : Google Scholar
|
|
4
|
Reddy GK, Gibson AD and Price N: Evolution
of FOLFOX regimens in the treatment of advanced colorectal cancer.
Clin Colorectal Cancer. 4:296–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shimizu T, Satoh T, Tamura K, et al:
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6)
in patients with refractory or advanced colorectal cancer:
post-approval Japanese population experience. Int J Clin Oncol.
2:218–223. 2007. View Article : Google Scholar
|
|
6
|
Leichman CG, Lenz HJ, Leichman L, et al:
Quantitation of intratumoral thymidylate synthase expression
predicts for disseminated colorectal cancer response and resistance
to protracted-infusion fluorouracil and weekly leucovorin. J Clin
Oncol. 15:3223–3229. 1997.
|
|
7
|
Salonga D, Danenberg KD, Johnson M, et al:
Colorectal tumors responding to 5-fluorouracil have low gene
expression levels of dihydropyrimidine dehydrogenase, thymidylate
synthase and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327.
2000.
|
|
8
|
Shirota Y, Stoehlmacher J, Brabender J, et
al: ERCC1 and thymidylate synthase mRNA levels predict survival for
colorectal cancer patients receiving combination oxaliplatin and
fluorouracil chemotherapy. J Clin Oncol. 19:4298–4304. 2001.
|
|
9
|
Kim SH, Kwon HC, Oh SY, et al: Prognostic
value of ERCC1, thymidylate synthase and glutathione S-transferase
pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Am J Clin Oncol. 32:38–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumamoto K, Kuwabara K, Tajima Y, et al:
Thymidylate synthase and thymidine phosphorylase mRNA expression in
primary lesions using laser capture microdissection is useful for
prediction of the efficacy of FOLFOX treatment in colorectal cancer
patients with liver metastasis. Oncol Lett. 3:983–989. 2012.
|
|
11
|
Stoehlmacher J, Park DJ, Zhang W, et al: A
multivariate analysis of genomic polymorphisms: prediction of
clinical outcome to 5-FU/oxaliplatin combination chemotherapy in
refractory colorectal cancer. Br J Cancer. 91:344–354. 2004.
|
|
12
|
Etienne-Grimaldi MC, Milano G,
Maindrault-Goebel F, et al: Methylenetetrahydrofolate reductase
(MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer
patients. Br J Clin Pharmacol. 69:58–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ruzzo A, Graziano F, Loupakis F, et al:
Pharmacogenetic profiling in patients with advanced colorectal
cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol.
25:1247–1254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boige V, Mendiboure J, Pignon JP, et al:
Pharmacogenetic assessment of toxicity and outcome in patients with
metastatic colorectal cancer treated with LV5FU2, FOLFOX and
FOLFIRI: FFCD 2000–05. J Clin Oncol. 28:2556–2564. 2010.PubMed/NCBI
|
|
15
|
Ma J, Stampfer MJ, Giovannucci E, et al:
Methylenetetrahydrofolate reductase polymorphism, dietary
interactions and risk of colorectal cancer. Cancer Res.
57:1098–1102. 1997.PubMed/NCBI
|
|
16
|
van der Put NM, Gabreëls F, Stevens EM, et
al: A second common mutation in the methylenetetrahydrofolate
reductase gene: an additional risk factor for neural-tube defects?
Am J Hum Genet. 62:1044–1051. 1998.PubMed/NCBI
|
|
17
|
Park DJ, Stoehlmacher J, Zhang W, et al:
ERCC1 gene polymorphism is associated with differential ERCC1 gene
expression. Proc AACR. 93:15912002.
|
|
18
|
Park DJ, Zhang W, Stoehlmacher J, et al:
ERCC1 gene polymorphism as a predictor for clinical outcome in
advanced colorectal cancer patients treated with platinum-based
chemotherapy. Clin Adv Hematol Oncol. 1:162–166. 2003.PubMed/NCBI
|
|
19
|
Chang PM, Tzeng CH, Chen PM, et al: ERCC1
codon 118 C>T polymorphism associated with ERCC1 expression and
outcome of FOLFOX-4 treatment in Asian patients with metastatic
colorectal carcinoma. Cancer Sci. 100:278–283. 2009.
|
|
20
|
Park DJ, Stoehlmacher J, Zhang W, et al: A
Xeroderma pigmentosum group D gene polymorphism predicts clinical
outcome to platinum-based chemotherapy in patients with advanced
colorectal cancer. Cancer Res. 61:8654–8658. 2001.
|
|
21
|
Stoehlmacher J, Park DJ, Zhang W, et al:
Association between glutathione S-transferase P1, T1 and M1 genetic
polymorphism and survival of patients with metastatic colorectal
cancer. J Natl Cancer Inst. 94:936–942. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen YC, Tzeng CH, Chen PM, et al:
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and
outcome of FOLFOX-4 treatment in Asian patients with colorectal
carcinoma. Cancer Sci. 101:530–535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zarate R, Rodríguez J, Bandres E, et al:
Oxaliplatin, irinotecan and capecitabine as first-line therapy in
metastatic colorectal cancer (mCRC): a dose-finding study and
pharmacogenomic analysis. Br J Cancer. 102:987–994. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watson MA, Stewart RK, Smith GB, et al:
Human glutathione S-transferase P1 polymorphisms: relationship to
lung tissue enzyme activity and population frequency distribution.
Carcinogenesis. 19:275–280. 1998. View Article : Google Scholar
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
26
|
Moscow JA, Fairchild CR, Madden MJ, et al:
Expression of anionic glutathione-S-transferase and P-glycoprotein
genes in human tissues and tumors. Cancer Res. 49:1422–1428.
1989.PubMed/NCBI
|
|
27
|
Ban N, Takahashi Y, Takayama T, et al:
Transfection of glutathione S-transferase (GST)-pi antisense
complementary DNA increases the sensitivity of a colon cancer cell
line to adriamycin, cisplatin, melphalan and etoposide. Cancer Res.
56:3577–3582. 1996.PubMed/NCBI
|
|
28
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
a systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stoehlmacher J, Goekkurt E, Mogck U, et
al: Thymidylate synthase genotypes and tumour regression in stage
II/III rectal cancer patients after neoadjuvant fluorouracil-based
chemoradiation. Cancer Lett. 272:221–225. 2008. View Article : Google Scholar
|
|
30
|
Dotor E, Cuatrecases M, Martínez-Iniesta
M, et al: Tumor thymidylate synthase 1494del6 genotype as a
prognostic factor in colorectal cancer patients receiving
fluorouracil-based adjuvant treatment. J Clin Oncol. 24:1603–1611.
2006. View Article : Google Scholar
|
|
31
|
Keam B, Im SA, Han SW, et al: Modified
FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase
II study and comprehensive analysis of polymorphisms as a
predictive and prognostic marker. BMC Cancer. 8:1482008. View Article : Google Scholar : PubMed/NCBI
|
